Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8215567.
- Also identified by PMC identifier 1029494.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An unselected series is presented of 17 infants born to epileptic mothers and exposed to sodium valproate during pregnancy. Nine infants had minor abnormalities and of these infants five also had major malformations, described as the 'fetal valproate syndrome'. The most frequent malformation was congenital heart disease. Nine of the infants had manifestations of withdrawal, such as irritability, jitteriness, abnormalities of tone, seizures, and feeding problems. Four of these infants had an unrelated hypoglycaemia. The frequency of withdrawal symptoms was significantly related to the dose of valproate given to the mothers in the third trimester, and there was a tendency for both the frequency of the minor abnormalities and the major malformations to be related to the valproate dosage in the first trimester.
Medical subject headings
- Heart Defects, Congenital
- Neonatal Abstinence Syndrome
- Prenatal Exposure Delayed Effects
- Valproic Acid